SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Neely who started this subject9/6/2001 9:19:50 AM
From: nigel bates  Read Replies (1) of 146
 
3-Dimensional Pharmaceuticals Announces Collaboration With Cyprotex for Predictive Drug Development Platform

EXTON, Pa., Sept. 6 /PRNewswire/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - news) today announced a collaboration with Cyprotex Limited of Manchester, UK, for use and refinement of Cyprotex's computerized methods for the prediction of human pharmacokinetics.
The collaboration is geared towards the application of Cyprotex ADME (absorption-distribution-metabolism-and excretion) prediction methods in parallel with 3DP's DiscoverWorks® small molecule drug discovery process to improve the success of pre-clinical drug optimization. Using data from compounds literally just ``out of the chemist's flask,'' Cyprotex' predictive ADME technology can model the compound's biological properties reducing the amount of laboratory work usually required to analyze such properties. 3-Dimensional Pharmaceuticals will work with Cyprotex to measure the power of this technology, testing Cyprotex modeling methods against 3DP's large and diverse chemical libraries. Financial details of the agreement were not disclosed.
``We are pleased with this opportunity to further advance our drug discovery and development process by evaluating these new capabilities,'' said David C. U'Prichard, Ph.D., Chief Executive Officer of 3DP. ``Our multi-tiered DiscoverWorks discovery process already accelerates the discovery of viable drug candidates. The Cyprotex methods should further improve the ADME properties of our drugs resulting in a higher probability that they will effectively treat diseases without unwanted side effects.''
UK-based Cyprotex Limited was founded in 1999 as an operating division of Medeval Limited, to develop the concept of predictive ADME, predictive toxicology and Drug-to-Drug Interaction (DDI) screening and to provide its customers with a fully automated mass compound high-throughput screening service. The Company's managing director is Dr. David Leahy, formerly Head of Physical Sciences at Zeneca Pharmaceuticals who joined Medeval to lead the development of Cyprotex.
Dr. Leahy's globally recognized expertise in drug candidate testing has allowed him to successfully collaborate with both the Medeval management team and academic groups at the University of Manchester in this ongoing endeavor...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News